Affiliation:
1. Department of Chemistry, University of Cyprus, 2109 Nicosia, Cyprus
2. Postgraduate Research Institute of Science, Technology, Environment and Medicine, 3021 Limassol, Cyprus
Abstract
Scandium (Sc) isotopes have recently attracted significant attention in the search for new radionuclides with potential uses in personalized medicine, especially in the treatment of specific cancer patient categories. In particular, Sc-43 and Sc-44, as positron emitters with a satisfactory half-life (3.9 and 4.0 h, respectively), are ideal for cancer diagnosis via Positron Emission Tomography (PET). On the other hand, Sc-47, as an emitter of beta particles and low gamma radiation, may be used as a therapeutic radionuclide, which also allows Single-Photon Emission Computed Tomography (SPECT) imaging. As these scandium isotopes follow the same biological pathway and chemical reactivity, they appear to fit perfectly into the “theranostic pair” concept. A step-by-step description, initiating from the moment of scandium isotope production and leading up to their preclinical and clinical trial applications, is presented. Recent developments related to the nuclear reactions selected and employed to produce the radionuclides Sc-43, Sc-44, and Sc-47, the chemical processing of these isotopes and the main target recovery methods are also included. Furthermore, the radiolabeling of the leading chelator, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), and its structural analogues with scandium is also discussed and the advantages and disadvantages of scandium complexation are evaluated. Finally, a review of the preclinical studies and clinical trials involving scandium, as well as future challenges for its clinical uses and applications, are presented.
Funder
University of Cyprus
Postgraduate Research Institute of Science, Technology, Environment and Medicine
a non-profit, charitable organization
Reference179 articles.
1. IAEA activities on 67Cu, 186Re, 47Sc theranostic radionuclides and radiopharmaceuticals;Jalilian;Curr. Radiopharm.,2021
2. Srivastava, S.C., and Mausner, L.F. (2013). Therapeutic radionuclides: Production, physical characteristics, and applications. Therapeutic Nuclear Medicine, Springer.
3. Paediatric Nuclear Medicine Practice: An International Survey by the IAEA;Poli;Eur. J. Nucl. Med. Mol. Imaging,2020
4. Radiopharmaceuticals for diagnosis in nuclear medicine: A short review;Payolla;Eclética Química,2019
5. Ilem-Ozdemir, D., Gundogdu, E.A., Ekinci, M., Ozgenc, E., and Asikoglu, M. (2019). Nuclear medicine and radiopharmaceuticals for molecular diagnosis. Biomedical Applications of Nanoparticles, William Andrew Publishing.